首页|米托蒽醌对前列腺癌骨痛缓解情况、临床疗效及安全性分析

米托蒽醌对前列腺癌骨痛缓解情况、临床疗效及安全性分析

The effect of mitoxantrone on prostate cancer and analysis of pain relief

扫码查看
目的 探讨米托蒽醌对前列腺癌的治疗效果及对缓解患者骨痛的效果.方法 回顾性分析2010年4月~2016年5月在天津中医药大学第一附属医院接受治疗的前列腺癌伴骨痛患者的临床资料,根据其治疗方式分为对照组和观察组,其中对照组40例,给予多西他赛治疗,观察组30例,给予米托蒽醌治疗.治疗2个疗程后,比较2组患者骨痛控制情况、睡眠质量、肿瘤标志物水平和不良反应发生率的差别.结果 治疗后,观察组骨痛控制有效率为96.67%,明显高于对照组,差异有统计学意义(P<0.05);观察组睡眠质量明显优于对照组,差异有统计学意义(P<0.05);观察组cPSA和CEA水平低于对照组,差异有统计学意义(P<0.05);2组患者骨髓抑制、恶心呕吐、皮疹和液体潴留发生率无明显差别(χ2=0.648,P=0.421).结论 米托蒽醌对前列腺癌有较好的治疗效果,可明显缓解患者骨痛情况和睡眠质量.
Objective To investigate the therapeutic effect of mitoxantrone on prostate cancer and the effect of relieving pain of patients.MethodsRetrospective analysis of clinical data of patients with bone pain in April 2010 to May 2016 year in our hospital for treatment of prostate cancer, according to their treatment divided into control group and observation group, the control group was 40 cases given docetaxel treatment, the observation group was 30 cases treated with mitoxantrone.Compared the pain relief, sleep quality, tumor markers and the incidence of adverse reactions of the two groups.ResultsAfter treatment, the observation group pain control rate was 96.67%, significantly higher than the control group, the difference was statistically significant (P<0.05);the observation group sleep quality was significantly better than the control group, the difference was statistically significant (P<0.05);the observation group cPSA and CEA were lower than those of control group, the difference was statistically significant (P<0.05).Two groups of patients with bone marrow suppression, nausea and vomiting, rash and liquid retention rate had no significant difference (χ2=0.648, P=0.421).ConclusionMitoxantrone has better therapeutic effect on prostate cancer, can significantly relieve the situation and quality of sleep in patients with bone pain.

mitoxantroneprostate cancersleep qualitytumor markers

易虎、赵明、何锦华

展开 >

天津中医药大学第一附属医院 泌尿外科,天津 300192

米托蒽醌 前列腺癌 睡眠质量 肿瘤标志物

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(6)
  • 8